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                                               ABSTRACT
The central composite design was used to develop the controlled release
buccoadhesive tablets containing losartan potassium. Locust bean gum
and hydroxy propyl methylcellulose K4M (HPMC K4M) were taken as
factors. Bioadhesive strength, drug release at  1 h, drug release at  8 h,
release exponent (n) and hardness were taken as responses. The polymers
had shown significant effect for all response.  A backing layer of ethyl
cellulose  was  used  which  is  impermeable  in  nature.  Nine  different
formulations of losartan potassium were prepared by direct compression
method.  The preformulation study using FTIR spectroscopy and  DSC
revealed  the  compatibility  of  drug  and  polymer.  The  prepared  tablets
were  characterized  by  swelling  studies,  surface  pH,  bioadhesive
properties and  In-vitro drug dissolution. All  the formulations gave the
satisfactory  results.  It  was  found  that  locust  bean  gum  gives  higher
bioadhesive  strength  than  HPMC  K4M.  Both  the  polymers  given
satisfactory swelling effect. The surface pH of all formulations was found
to be satisfactory, and values of pH were in between the range of 5-7,
hence no irritation to buccal cavity is assumed. All the tablets showed ex
vivo residence time of 7.2 h to >10 h indicated good adhesive capacity of
tablet. The  optimized  formulation  follows  Fickian  diffusion  release
mechanism. Stability study was carried out for optimized formulation as
per ICH guidelines and no major change was observed.
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1. INTRODUCTION
For many decades, treatment of an acute disease or a chronic illness has been
mostly accomplished by delivering drugs  using various pharmaceutical  dosage forms,
including tablets, capsules, pills, suppositories, creams, ointments, liquids, aerosols and
injectables as carriers. Amongst various routes of drug delivery oral route is perhaps the
most preferred to the patient and the clinician alike. However this route presents some
problems for  a  few drugs.  The enzymes in  the GI fluids,  GIT-pH conditions and the
enzymes bound to GIT membranes are a few factors responsible for the bioavailability
problems. The blood that drains the GIT carries the drug directly to the liver leading to
first-pass metabolism resulting in poor bioavailability. The inherent problems associated
with the drug in some cases can be solved by modifying the formulation or by changing
the  routes  of  administration.  Parenteral,  mucosal  and  transdermal  routes  circumvent
hepatic first-pass metabolism and offer alternative routes for the systemic delivery of
drugs1.
In recent years,
 the interest in novel routes of drug administration occurs from
their ability to enhance the bioavailability of drugs. Drug delivery via the buccal route
using  bioadhesive  dosage  forms  offers  such  a  novel  route  of  drug  administration.
Extensive  first-pass  metabolism  and  drug  degradation  in  the  harsh  gastrointestinal
environment can be circumvented by administering the drug via buccal route 2.
The thin mucin film, which exists on the surface of the oral mucosa may provide
an opportunity to retain a drug delivery system in contact with the mucosa for prolonged
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periods if it is designed to be mucoadhesive. Such system ensures a close contact with
absorbing  membrane,  thus  optimizing  the  drug  concentration  gradient  across  the
biological membrane and reducing the differential pathway. Therefore, the oral mucosa
may be  a  potential  site  for  controlled  or  sustained  drug delivery.  In  this  respect,  the
buccal and gingival areas are associated with a smaller flow of saliva, as compared to the
sublingual region, thus the duration of adhesion of the delivery system would be longer at
these areas than at the sublingual region3.
Buccal route provides one of the potential routes for typically large, hydrophilic
and unstable proteins, oligonucleotides and polysaccharides as well as conventional small
drug molecules. The oral cavity can be used for local and systemic therapy. Examples of
local therapy would be the treatment of oral infections, dental caries, mouth ulcers and
stomatitis. The buccal route is of particular interest with regard to the systemic delivery
of small molecules that are subjected to first pass metabolism or for the administration of
proteins and peptides4.
Cardiovascular diseases account for a large proportion of all deaths and disability
worldwide. Global Burden of Disease (GBD) Study reported that there were 5.2 million
deaths from cardiovascular diseases in economically developed countries and 9.1 million
deaths from the same causes in developing countries. Worldwide prevalence estimates for
hypertension may be as much as 1 billion individuals, and approximately 7.1 million
deaths per year may be attributable to hypertension. Hypertension is directly responsible
for  57% of  all  stroke deaths  and  24% of  all  coronary heart  disease  deaths  in  India.
Pooling of  Indian epidemiological  studies  shows  that  hypertension  is  present  in  25%
urban and 10% rural subjects. Therefore cost effective approaches to optimally control
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blood  pressure  among  Indians  are  very  much  needed.  Although  novel  drug-delivery
systems have been used in other areas of medicine, their application in the treatment of
hypertension has been relatively recent5.
1.1 Drug delivery via buccal route:
Buccal delivery refers to drug release which can occur when a dosage form is
placed in the outer vestibule between the buccal mucosa and gingiva. Various advantages
and other aspects of this route are elucidated of the following.
Avantages of Buccal Drug Delivery Systems4,6:
Drug administration via buccal mucosa offers several distinct advantages,
1. Ease of administration.
2. Permits localization of the drug in the oral cavity for a prolonged period of time.
3. Offers excellent route for systemic delivery of drugs with high first pass metabolism,
thereby offering a greater bioavailability.
4. A significant reduction in dose can be achieved, thereby reducing dose dependent side
effects.
5. Drugs which are unstable in acidic environment of the stomach or are destroyed by the
enzymatic or alkaline environment of the intestine.
6. The presence of saliva ensures relatively large amount of water for drug dissolution
unlike the case of rectal and transdermal routes.
7. It offers passive system for drug absorption and does not require any activation.
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8. It can be made unidirectional to ensure only buccal absorption.
9.  The  buccal  mucosa  is  highly  perfused  with  blood  vessels  and  offers  greater
permeability than the skin.
10. Therapeutic serum concentrations of the drug can be achieved more rapidly.
11. Better patient compliance than vaginal, rectal and nasal route of administration.
12. Buccal mucosa is less prone to damage or irritation than nasal mucosa and shows
short recovery times after stress or damage.
13. Termination of therapy is easy.
14. Can be administered to unconscious patients.
15. Increased patient’s compliance.
Disadvantages of buccal drug delivery system4,6:
Drug administration via buccal mucosa has certain limitations,
1. Drugs which irritate the oral mucosa have a bitter or unpleasant taste or odour cannot
be administered by this route.
2. Drugs, which are unstable at buccal pH, cannot be administered by this route.
3. Only drugs with small dose requirements can be administered.
4. Drugs may get swallowed with saliva and loses the advantages of buccal route.
5. Only those drugs, which are absorbed by passive diffusion, can be administered by this
route.
6. Over hydration may lead to the formation of slippery surface and structural integrity of
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the  formulation  may get  disrupted  by the  swelling  and  hydration  of  the  bioadhesive
polymers.
7. Surface area available for absorption is less.
8. The buccal mucosa is relatively less permeable than the small intestine, rectum, etc.
1.2 Anatomy and Nature of Oral Cavity:
1.2.1 Oral Cavity7:
Oral cavity is  the foremost part of digestive system of human body due to its
excellent  accessibility  and  reasonable  patient  compliance,  oral  mucosal  cavity  offers
attractive route of drug administration for the local and syste mic therapy.
1.2.2 Overview of oral cavity:
Oral cavity is that area of mouth delineated by the lips, cheeks, hard palate, soft
palate and floor of mouth. The oral cavity consists of two regions,
1.  Outer  oral  vestibule,  which  is  bounded  by cheeks,  lips,  teeth  and  gingival
(gums).
2.  Oral  cavity  proper,  which  extends  from teeth  and  gums  back  to  the  faces
(which lead to pharynx) with the roof comprising the hard and soft palate. The tongue
5
projects from the floor of the cavity.
The drug administered via the oral mucosa gain access to the systemic circulation
through a network of arteries and capillaries. The major artery supplying the blood to the
oral cavity is the external carotid artery. The venous backflow goes through branches of
capillaries and veins and finally taken up by the jugular vein8. The secretion in the oral
cavity includes saliva, crevicular fluid and mucus. From that, Saliva is a complex fluid
containing organic and inorganic materials. It  is produced by the three pairs of major
glands (parotid submandibular and sublingual) each situated outside the oral cavity and in
minor salivary glands situated in the tissues  lining most of  the oral  cavity.  The total
average volume of saliva produced daily in an adult is around 750 ml. The flow rates of
saliva depend upon the type of stimulus used, the time of day, the length of time, glands
had been stimulated, the age and sex of the individual and by their state of health. The
average resting flow rate  for  whole saliva is  0.3  ml/min (range 0.1-0.5  ml/min).  For
stimulated  saliva  the  average  flow  rate  is  1.7ml/min  (range  1.1  to  3.0  ml/min).
Chemically, saliva is 99.5% water and 0.5% solutes. The solutes include ions (sodium,
potassium, magnesium, phosphate, bicarbonate and chloride), dissolved gases, urea, uric
acid, serum albumin, globulin, mucin and enzymes9.
1.3 Oral Mucosa:
1.3.1 Anatomy and physiology of the oral mucosa:
The  mucosa  that  lines  the  oral  cavity  may  be  divided  into  three  types,  classified
according to their function as;
1. Masticatory mucosa: Which includes the mucosa around the teeth and on the
hard palate and these regions have keratinized epithelium.
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2. Lining mucosa: Which covers the lips, cheeks, fornix, base of the oral cavity,
lower part of tongue, buccal mucosa and the soft palate and these regions have non-
keratinized epithelium.
3.  Specialized  mucosa:  covering  the  dorsum  of  the  tongue  with  highly
keratinization. Light microscopy reveals several distinct patterns of maturation in the
epithelium of the human oral mucosa based on various regions of the oral  cavity.
Three distinctive layers of the oral mucosa are the epithelium, basement membrane
and connective tissues. The oral cavity is lined with the epithelium, below which lies
the supporting basement membrane. The basement membrane is in turn supported by
connective tissues (Fig 2). The epithelial cells originating from the basal cells mature
change  their  shape  and  increase  in  size  while  moving  towards  the  surface.  The
thickness of buccal epithelium in humans, dogs and rabbits has been determined to be
approximately  500–800  µm.  The  basement  membrane  forms  a  distinctive  layer
between the connective tissues and the epithelium. It provides the required adherence
between  the  epithelium and  the  underlying  connective  tissues  and  functions  as  a
mechanical support for the epithelium. 
.
                                Figure 2: Structure of buccal mucosa
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1.3.2 Mechanisms involved in drug absorption across the oral mucosa:
The mechanisms by which drugs cross biological lipid membranes are passive diffusion,
facilitated diffusion, active transport and pinocytosis. Small water-soluble molecules may
pass through, small water filled pores. The main mechanism involved in drug transfer
across the oral mucosa, is passive diffusion has also been shown to take place, primarily
with nutrients. Passive diffusion involves the movement of a solute from a region of high
concentration in the mouth to a region of low concentration within the buccal tissues.
Further  diffusion  then  takes  place  into  the  venous  capillary  system,  with  the  drug
eventually reaching the systemic circulation via the jugular vein. The physicochemical
characteristics of a drug are very important for this diffusion process. The permeability
barrier property of the oral mucosa is predominantly due to intercellular materials derived
from the so-called,  membrane coating granules  (MCGs).  MCGs are spherical  or  oval
organelles  that  are  100–300 nm in  diameter  and  found  in  both  keratinized and  non-
keratinized epithelia. These organelles have also been referred to as small spherically
shaped granules “corpusula”, small dense granules, small lamellated bodies, lamellated
dense bodies, keratinosomes, transitory dense bodies and cementsomes. MCGs are found
near the upper, distal or superficial border of the cells and a few occur near the opposite
border.  Several  hypotheses  have  been  suggested  to  describe  the  functions  of  MCGs
including a membrane thickening effect, cell adhesion, production of a cell surface coat,
cell  desquamation  and  permeability  barrier.  They  discharge  their  contents  into  the
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intercellular  space  to  ensure  epithelial  cohesion  in  the  superficial  layers  and  this
discharge forms a barrier to the permeability of various compounds1
1.4. TYPES OF BUCCAL DRUG DELIVERY SYSTEM12, 6:
For  delivery of drug through buccal  region several  mucoadhesive dosage forms have
been reported because of the presence of a smooth and relatively immobile surface for
placement of a mucoadhesive dosage forms the buccal region appears to be more suitable
for sustained delivery of therapeutic agents using a mucoadhesive system. The various
types of buccal drug delivery system are explained as follows;
1. Buccal Tablets
2. Buccal Patches and Films
3. Buccal Semisolids (ointments and gels)
4. Buccal Powders
1. BUCCAL TABLETS
 Adhesive tablets are held between the gum and cheek.
 Generally flat, elliptical or capsule-shaped.
 Troches & lozenges are two other types of tablets used in oral cavity where they
are intended to exert a local effect in the mouth or throat.
 Buccoadhesive tablet may be monolithic or bilaminated system.
 Monolithic is multidirectional release.
 Bilayered containing core layer & backing layer.
 Backing  layer  may  be  of  water  insoluble  material  like  Ethyl  cellulose  or
hydrogenated caster oil or may be polymeric coating layer.
 Backing layer avoids sticking of the tablet to the finger during application.
LIMITATIONS OF BUCCAL TABLETS
 The small surface of contact with mucosa.
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 Their lack of physical flexibility.
 It is difficult to get high release rate, which is required for some drugs.
 The  extent  and  frequency  of  contact  may  cause  irritation  following  chronic
application of the buccal mucosa.
2. BUCCAL PATCHES AND FILMS
Buccal patches consists of two ply laminates or multilayered thin film round or oval as
consisting of basically of bioadhesivc polymeric layer and impermeable backing layer to
provide unidirectional flow of drug across buccal mucosa. Buccal bioadhcsivc films are
formulated by incorporating the drug in alcohol solution of bioadhesive polymer.
Example:
 Isosorbid  dinitrate  in  the  form  of  unidirectional  errodible  buccal  film  are
developed and characterised for improving bioavailability.
 Buccal film of salbutamol sulphate and terbutalin sulphate for the treatment of
asthma.
 Buccoadhesive film of clindamycin used for pyorrhoea treatment.
3. BUCCAL SEMISOLID DOSAGE FORMS
A buccal semisolid dosage form consists of finally powdered natural or synthetic polymer
dispersed in a polyethylene or in aqueous solution. Example: Gels, Ointments, orabase
 Gels  are  usually  clear,  transparent,  semisolids  containing  solubilized  active
substances. Forming hydrophilic polymers is typically used to prepare lipid-free
semisolid dosage forms.
E.g: Methylcellulose, carbopols, hydroxyl ethylcellulose etc.
 Vehicles  containing  therapeutic  agents  are  especially  useful  for  application  to
mucus  membranes  and  ulcerated  or  burned  tissues,  because  their  high  water
content reduces irritancy.
 Due to plastic rheological behaviour they can remain to the surface of application
for a reasonable duration before they are washed off.
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 In  comparison  to  solutions,  gels  can  significantly  prolong  residence  time  and
hence improve bioavailability. Eg. Glibenclamide
 One of the original oral mucosal-adhesive delivery systems- “orabase” consists of
finely ground pectin, gelatin and sodium carboxy methyl cellulose dispersed in a
poly (ethylene) and a mineral oil gel base, which can be maintained at its site of
application for 15-150 minutes.
4. BUCCAL POWDER DOSAGE FORMS
Buccal bioadhesive powder dosage forms are a mixture of bioadhesivc polymers and the
drug and are sprayed onto the buccal mucosa.
1.5. Conventional Dosage Form 13:
The conventional type of buccal dosage forms are buccal tablets, troches and lozenges
and mouth washers. Buccal tablets are small, flat, oval tablets and are intended to be held
between the cheek and the teeth or in the cheek pouch (buccal  tablets).  Progesterone
tablets can be administered this way. Troches and lozenges are two other types of tablets
used in oral cavity where they are intended to exert a local effect in the mouth or throat.
These tablet  forms are commonly used to  treat  sore throat  or  to  control  coughing in
common  cold.  Lozenges  (pastilles  or  cough  drops)  are  usually  made  with  the  drug
incorporated  in  a  flavoured,  hard-candy  sugar  base.  Lozenges  may  be  made  by
compression but are usually formed by fusion or by a candy–moulding process.  Troches,
on the other  hand,  are manufactured by compression as  are other  tablets.  These two
classes of tablets are designed not to disintegrate in the mouth but to dissolve or slowly
erode over a period of perhaps minute or less.
1.6. MUCOADHESSION/BIOADHESION14: -
Bioadhesion can be  defined as  a  phenomenon of  interfacial molecular attractive  forces
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amongst the surfaces of  the biological substrate  and the  natural or synthetic polymers,
which allows the polymer to adhere to the biological surface for an extended period of
time. These systems have been used since long time in the development of products for
various biomedical applications.
1.6.1. Theories of bioadhesion/mucoadhesion:
The mechanism ob bioadhesion follows complex formation. There are six theories that
explain  the  detailed  theory of  mucoadhesion  or  bioadhesion.  Bioadhesion  take  place
between  a  biological  substance  and  with  a  synthetic  or  natural  polymer.  When  the
biological substrate is a mucosal layer then the phenomena is known as mucoadhesion.
The theories include,
a. Electronic theory
b. Wetting theory
c. Adsorption theory
d. Diffusion theory
e. Mechanical theory
f. Cohesive theory
a) Electronic theory
This theory is based on the assumption that the bioadhesive material and the glycoprotein
mucin  network  have  different  electronic  structures.  When the  two materials  come in
contact with each other electron transfer will occur causing the formation of a double
layer of electrical charge at the interface. The bioadhesive force is due to attractive forces
across  this  electrical  double layer.  The system is  charged when the adhesive and the
substrate are in contact and discharged when they are separated. However, this theory has
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caused  some controversy  regarding  whether  the  electrostatic  forces  are  an  important
cause or the result of the contact between the bioadhesive and the biological tissue.
b) Wetting theory
The  wetting  theory  was  based  upon  prediction  of  the  intimate  contact  between  the
mucoadhesive  polymer  and  the  mucous  leading  to  dispelling  of  barrier  substances,
spreading,  and  subsequent  adhesion,  in  liquid  state,  utilizing interfacial  tension.  This
theory  involves  calculation  of  the  contact  angle  and  the  thermodynamic  work  of
adhesion; and the work done related to the surfacetension of both the adhesive and the
substrate,  calculated  with  the  Dupre’s  equation  (Pritchard  WH.  1970),  the  horizontal
resolution of the forces with the Young equation, and the spreading coefficient (Sb).
Dupre’s equation: ωA = γb + γτ - γbt
Young equation: γta = γbt + γbaCOSθ
Spreading coefficient: Sb = γta - γbt – γba
Where  ωA was  the  specific  thermodynamic  work  of  adhesion  and  γb represents  the
surface  tensions  of  the  bioadhesive  polymer,  γτ represents  the  surface  tension of  the
substrate, γbt represent the interfacial tension between the tissue and polymer, θ represent
the angle of contact,  γba represent the interfacial tension between polymer and air, and
γta  represent  the interfacial  tension between tissue and air.  Young equation state  that
wetting will be complete if θ will approach zero, that was the vector γta greatly exceeds
γbt + γba; while a θ vale greater than zero will result in incomplete wetting. In order to
achieve  adhesion  of  mucoadhesives  to  a  biological  membrane  spreading  coefficient
should be positiv that is bioadhesion is favoured by large values of γta or by small values
of γbt and γba
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c) Adsorption theory
According  to  adsorption  theory  mucoadhesion  results  from  secondary  molecular
interactions like electrostatic attraction, hydrophobic interactions, hydrogen bonds, van
der Waals forces, or other related forces; associated with re-orientation of polar molecules
or groups at the interface or with chemisorptions
d) Diffusion theory
The diffusion theory states that interpenetration of the chains of polymer and mucin to a
sufficient  depth  results  from  the  existing  concentration  gradients  and  consequential
interpenetration; until an equilibrium penetration depth was achieved, in the range of 0.2
to  0.5  µm;  creates  a  semi-permanent  bond  through  entanglement  and  mechanical
interlocking between mucin and mucoadhesives. The mean diffusional depth (S) of the
bioadhesive  polymer  segments  can  be  calculated  from  contact  time  (t)  and
diffusioncoefficient value (D) with the following relation.
                                                      S = (2tD).
But  the  time to  bioadhesion of  a  particular  polymezr  (t)  can  be  calculated  from the
diffusion  coefficient  of  a  bioadhesive  through  the  substrate  value  (Db)  and  the
interpenetrating depth (l), with the following relation.
t = l2/Db
e) Fracture theory
The fracture theory was based on analysis othe force required for the separation of two
surfaces after adhesion using tensile apparatus employing following relation that relates
fracture strength (σ),  fracture energy (є),  young modulus of  elasticity (E)  and critical
crack length (L).                                                                         σ = (E × є/L).
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1.6.2. Factors affecting mucoadhesion in the oral cavity15,11:-
Mucoadhesive  characteristics  are  a  factor  of  both  the  bioadhesive  polymer  and  the
medium in which the polymer will reside. A variety of factors affect the mucoadhesive
properties of polymers, such as molecular weight, flexibility, hydrogen bonding capacity,
cross-linking density, charge, concentration, and hydration (swelling) of a polymer, which
are briefly addressed below.
Polymer-related factors
1.6.2.1. Molecular weight.
In general, it has been shown that the bioadhesive strength of a polymer increases
with molecular weights above 100,000. 
1.6.2.2. Flexibility.
Bioadhesion starts with the dif- fusion of the polymer chains in the interfacial
region. Therefore, it is important that the polymer chains contain a substantial degree of
flexibility  in  order  to  achieve  the  desired  entanglement  with  the  mucus.  A recent
publication demonstrated the use of tethered  poly (ethylene glycol),  poly  (acrylic
acid)  hydrogels and their  copolymers  with improved mucoadhesive properties.
The increased chain interpenetration was attributed to the increased struc-tural flexibility
of the polymer upon incorporation of poly (ethylene glycol). In general,  mobility and
flexi-bility  of  polymers  can  be  related  to  their  viscosities  and  diffusion  coefficients,
where higher flexibility of a polymer causes greater diffusion into the mucusnetwork .
1.6.2.3. Hydrogen bonding capacity.
Hydrogen bonding is another important factor in mucoadhesion of a polymer. Park and
Robinson found that in order for mucoadhesion to occur, desired polymers must have
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functional groups that are able to form hydrogen bonds.  They have also confirmed that
flexibility  of  the  polymer  is  important  to  improve  this  hydrogen  bonding  potential.
Polymers such as poly (vinyl alcohol), hydroxylated methacrylate, and poly (methacrylic
acid), as well as all their copolymers, are polymers with good hydrogen bonding capacity.
1.6.2.4. Cross-linking density.
The  average  pore  size,  the  number  average  molecular  weight  of  the  cross-linked
polymers, and the density of cross-linking are three important and interrelated structural
parameters of a polymer network.  Therefore,  it  seems reasonable that with increasing
density of cross-linking, diffusion of water into the polymer net-work occurs at a lower
rate which, in turn, causes an insufficient swelling of the polymer and a decreased rate of
interpenetration between polymer and mucin.  
 
1.6.2.5. Charge.
Some  generalizations  about  the  charge  of  bioadhesive  polymers  have  been  made
previously,  where nonionic polymers  appear to  undergo a smaller degree of  adhesion
compared to anionic polymers. Peppas and Buri have demonstrated that strong anionic
charge on the polymer is one of the required characteristics for mucoadhesion. It has been
shown  that  some cationic  polymers  are  likely to  demonstrate  superior  mucoadhesive
properties, especially in a neutral or slightly alkaline medium. Additionally, some cationic
high molecular weight polymers, such as chitosan, have shown to possess good adhesive
properties.
1.6.2.6. Concentration.
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The importance of this factor lies in the development of a strong adhesive bond with the
mucus, and can be explained by the polymer chain length available for penetration into
the  mucus  layer.  When  the  concentration  of  the  polymer  is  too  low,  the  number  of
penetrating polymer chains per unit volume of the mucus is small, and the interaction
between  polymer  and  mucus  is  unstable.  In  general,  the  more  concentrated  polymer
would result in a longer penetrating chain length and better adhesion. However, for each
polymer,  there  is  a  critical  concentration,  above  which  the  polymer  produces  an
unperturbed state due to a significantly coiled structure. As a result, the accessibility of
the solvent to the polymer decreases, and chain penetration of the polymer is drastically
reduced. Therefore, higher concentrations of polymers do not necessarily improve and, in
some cases,  actually diminish mucoadhesive properties. One of the studies addressing
this factor demonstrated that high concentrations of flexible polymeric films based on
polyvinylpyrrolidone or poly (vinyl alcohol) as film-forming polymers did not further
enhance the mucoadhesive properties of the polymer.  On the contrary, it decreased the
desired strength of mucoadhesion.
1.6.2.7. Hydration (swelling).
Hydration  is  required  for  a  mucoadhesive  polymer  to  expand  and  create  a  proper
macromolecular  mesh  of  sufficient  size,  and  also  to  induce  mobility  in  the  polymer
chains  in  order  to  enhance  the  interpenetration process  between  polymer  and  mucin.
Polymer swelling permits a mechanical entanglement by exposing the bioadhesive sites
for  hydrogen  bonding  and/or  electrostatic  interaction  between  the  polymer  and  the
mucous network. However, a critical degree of hydration of the mucoadhesive polymer
exists where optimum swelling and bioadhesion occurs.
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1.6.2.8. Environmental factors
The mucoadhesion of a polymer not only depends on its molecular properties, but also on
the  environmental  factors  adjacent  to  the  polymer.  Saliva,  as  a  dissolution  medium,
affects the behavior of the polymer. Depending on both the saliva flow rate and method
of determination, the pH of this medium has been estimated to be between 6.5 and 7.5.
The pH of the microenvironment surrounding the mucoadhesive polymer can alter the
ionization state and, therefore, the adhesion properties of a polymer. Mucin turnover rate
is another environmental factor. The residence time of dosage forms is limited by the
mucin turnover time, which has been calculated to range between 47 and 270 min in rats
and 12–24 h in  humans. Movement  of the buccal  tissues  while  eating,  drinking,  and
talking, is another concern which should be considered when designing a dosage form for
the oral cavity. Movements within the oral cavity continue even during sleep, and can
potentially lead to the detachment of the dosage form. Therefore, an optimum time span
for the administration of the dosage form is necessary in order to avoid many of these
interfering factors.
Ideal drug candidates for buccal drug delivery System16
 The conventional single dose of drug should be low.
 Through oral  route,  the drug may exhibit  first  pass effect  or  presystemic drug
elimination.
 The drug should not adversely affect the natural microbial flora or oral cavity.
 Drug  should  not  have  bad  taste  and  be  free  from  irritancy,  allergenicity  and
discoloration or erosion of teeth.
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Marketed products17
Buccal mucosa formulations
Buccastem- manufactured by reckitt and colman in United Kingdom.
Suscard Buccal- manufactured by Pharmax.
1.7. Mucoadhesive polymers used in the oral cavity18,11:
1.7.1. Desired characteristics:
The  polymer-related  factors  have  been  briefly  discussed  in  the  previous  section.
Generally,  some  of  the  necessary  structural  characteristics  for  bioadhesive  polymers
include  strong  hydrogen  bonding  groups,  strong  anionic  or  cationic  charges,  high
molecular weight, chain flexibility, and surface energy properties favoring spreading on a
mucus layer.
1.7.2. Classification:
In general, adhesive polymers can be classified as synthetic vs. natural, water soluble vs.
water insoluble, and charged vs. uncharged polymers. Examples of the recent polymers
classified in these categories are listed in  Table.  Natural  bioadhesive macromolecules
share similar structural properties with the synthetic polymers. They are generally linear.
Criteria Categories Examples
Source Semi-
atural/natural
Synthetic
Agarose,  chitosan, gelatin, Hyaluronic acid,  Various gums
(guar,  hakea,  xanthan,  gellan,  carragenan,  pectin,  and
sodium alginate, locust bean gum).
Sodium CMC, HEC, HPC,
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HPMC, Carbopol etc.
Aqueous
solubility
Water-soluble
Water-nsoluble
CP,  HEC,  HPC,  HPMC,  PAA,  sodium  CMC,  sodium
alginate
Chitosan, EC, PC
Charge Cationic
Anionic
Non-ionic
Aminodextran, chitosan, trimethylated Chitosan
Chitosan-EDTA,  CP,  CMC,  pectin,  PAA,  PC,  sodium
alginate, sodium CMC, xanthan gum.
Hydroxyethyl starch, HPC, PVA, PVP
Forces Covalent
Hydrogen bond
Electrostatic
Interaction
Cyanoacrylate
Acrylates, CP, PVA
Chitosan
Table 1: Classification of mucoadhesive polymers in buccal drug delivery
 
1.7.3.  CHARACTERISTICS  OF  AN  IDEAL  MUCOADHESIVE
POLYMER:
1. Rapid adherence to mucosa.
2. Exhibit strong interaction with the mucin epithelial tissue.
3. Minimum impact on drug release.
4. Good spreadability, wetting, swelling and solubility and biodegradability properties.
5. Unaffected by the hydrodynamic conditions, food and pH changes.
6. Easy to incorporate in various dosage forms.
7. Possess peel, tensile and shear strengths at the bioadhesive range.
8. Show bioadhesive properties in both dry and liquid state.
9. Demonstrate local enzyme inhibition and penetration enhancement properties.
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10. Demonstrate acceptable shelf life.
11. Optimum molecular weight.
12. Possess adhesively active groups.
13. Possess required spatial conformation.
14. Sufficiently cross-linked but not to the degree of suppression of bond forming groups.
15. Possess good viscoelastic properties and no breakdown at the mucosa.
1.8. OPTIMIZATION119
The word optimize is defined as, to make as perfect, effective or functional as possible.
Optimization may be interpreted as to find out the values of controllable independent
variables, that gives the most desired value of dependent variables. In the trial and error
method, a lot of formulations have to be prepared to get a conclusion, which involves lot
of money, time and energy. These can be minimized by the use of optimization technique.
1.8.1. Optimization process:
Generally optimization process involves the following steps
1. Based on the previous knowledge or experience or from literature, the independent
variables are determined or set in the beginning.
2. Selection of a model based on the results of the factor screening.
3. The experiments are designed and are conducted.
4. The responses are analyzed by ANOVA, test on lack of fit,  to get an empirical
mathematical model for each individual response.
5.  The  responses  are  screened  by  using  multiple  criteria  to  get  the  values  of
independent variables.
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1.8.2. Experimental design20
Experimental design is a statistical design that prescribes or advises a set of combination
of  variables.  The  number  and  layout  of  these  design  points  within  the  experimental
region,  depends  on  the  number  of  effects  that  must  be  estimated.  Depending on  the
number of  factors,  their  levels,  possible  interactions  and order  of  the model,  various
experimental designs are chosen. Each experiment can be represented as a point within
the experimental domain, the point being defined by its co-ordinate (the value given to
the variables) in the space.
a) Factorial design
It  is an experimental design, which uses dimensional factor space at the corner of the
design space.  Factorial designs are used in experiments where the effects of different
factors or conditions on experimental results are to be elucidated. These are the design of
choice  for  simultaneous  determination  of  the  effect  of  several  factors  and  their
interaction.
The simplest factorial design is the two-factorial design where two factors are considered
each at two levels, leads to four experiments, which are situated in 2-dimensional factor
space at the corners of a rectangle. If  there are three factors, each at two levels, eight
experiments are necessary which are situated at the corners of an orthogonal cube in a 3-
dimensional space. The number of experiments is given by 2n, where ‘n’ is the number of
factors.
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If  the number of factors and levels are large,  then the number of experiments
needed to complete a factorial  design is  large.  To reduce the number of experiments,
fractional factorial design can be used (i.e., ½ or ¼ of the original number of experiments
with full factorial design).
The  fitting  of  an  empirical  polynomial  equation  to  the  experimental  result
facilitates the optimization procedure. The general polynomial equation is as follows:
Y = B0  + B1X1  +  B2X2  + B3X3  +…+ B12X1X2  + B13X1X3  + B23X2X3  +…+
B123X1X3.
Where, Y is the response,
X1, X2, X3 are the levels (concentration) of the 1,2,3 factors
B1, B2, B3, B12, B13, B23, B123, are the polynomial coefficients.
B0 is the intercept (which represents the response when the level of all factors is low).
b) Plackett – Burman design
It is a special fractional factorial design with K = m*4 experiment, for screening of (K-1)
variables, Where ‘K’ is the number of variables and ‘m’ is the number of levels.
c) Star design
Star design is simply a 22 factorial design rotated over 450 angle in the space. A center
point is usually added, which may be replicated to estimate the experimental error, so
there will be three levels for each factor where quadratic effect can be measured, but the
interaction  effect  cannot  be  measured  as  that  in  case  of  factorial  design.  In  the  star
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designs,  2k Factorial designs are rotated over 450  in (k-1) direction in k-dimensional
space with a replicated center point. ‘k’ is the number of factors in the design. This results
in 2k + R
c 
experiments, where R
c 
is the replicates of the center point.
d) Central Composite design
A better design that combines the advantages of Factorial design or Fractional factorial
design and the Star design, is the central composite design (CCD) developed by Box and
Wilson. It is composed of
• 2k Factorial design or 2(k-p) Fractional factorial design.
• 2*k Star design, this design enables the estimation of a full second-order model. The
equation for two factors is given by
E(y) = B
0+B1X1+B2X2+B12X1X2+B11X1
2+B22X2
2
1.8.3. Validation of the model
The  model  is  validated  using  ANOVA calculation,  then  the  estimation  pure
measurement error is done. The variance of these observations pooled over all to get an
estimate of pure error of variance. The F-test on regression and lack of fit will be useful
for judging descriptive properties of a model and the significance of model terms.
1.8.4. Predictions using the selected model
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Once  a  model  is  selected  and  validated,  the  brute  force  method  is  applied  for  the
prediction of response. With the help of 3D-response surface or a 2D contour diagram,
the  prediction  is  done  using  these  graphs  either  by  grid  search  or  feasibility  search
methods.
1.9. Software for designs and Optimization22
Many commercial software packages are available which are either dedicated to
experimental design alone or are of a more general statistical type.
1.9.1. Software’s dedicated to experimental designs
Design Ease and Design Expert (Stat-ease)
• ECHIP
• CARD
• Multisimplex
Software for general statistical nature includes
• SAS
• MINITAB
• SYSTAT, etc.
JUSTIFICATION
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For my dissertation work of formulation and evaluation of mucoadhesive buccal tablets
by using central composite design for anti hypertensive drug; selected.
The main reason for the selection of losartan potassium for the formulation, it has less
bioavailability (33%) due to the high first pass metabolism and it has very short half  life
2.5 h and for controlled release formulation the half life should be less.
The polymer locust bean gum is a very good mucoadhesive polymer and it has a good
gelling capacity. It is also controlle the drug release.
2. OBJECTIVES:
The objective  of  the  present  research  work  is  to  formulate  and  evaluate  bilayered
buccoadhesive tablet containing losartan potassium as a drug to achieve unidirectional
drug release and to increase bioavailability of the drug.   
The specific objectives of the present research include:
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1. Locust bean gum  will  be  selected as  a  primary  polymer  along  with  HPMC
K4M as  secondary polymer for the preparation of mucoadhesive buccal tablets.
2. To confirm the conjugation primarily by determining charring point and further
by performing FT-IR and differential scanning calorimetry.
3. To formulate bilayered buccoadhesive tablet by using combination of locustbean
gum along with other polymers using losartan potassium as a model drug having
prolonged residence time and ethyl cellulose as an impermeable membrane. 
4. To  evaluate  the  physical  characteristics  like  weight  uniformity,  thickness,
hardness and drug content of the formulations. 
5. To evaluate mucoadhesive characteristics like swelling index, ex vivo bioadhesion
time and ex vivo bioadhesion strength. 
3. REVIEW OF LITERATURE
3.1 REVIEW OF LITERATURE:
 Reviews  of  literatures  revealed  that  number  of  studies  have  been  carried  out  on
mucoadhesive buccal tablets using different techniques.
 The drug has selected as an anti hypertensive drug in Essential medical pharmacology
and the drug of the anti hypertensive is studied as its properties molecular weight,
half life, bioavailability and it avoids the first pass metabolism.22
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 The aim of the current study was to develop the UV- spectrophotometric method for
the estimation for Losartan potassium in solid pharmaceutical dosage form. The λ-
max of losartan potassium was found to be 234nm to both crude and marketed sample
and is  analyzed  using Beer-Lamberts  law.  The developed  methods  were  absolute,
definite, explicit and consistent and found to be a prototype for routine determination
for  losartan  potassium.  The  method  was  validated  statistically  and  by  recovery
studies. The LOD (limit of detection) and LOQ (limit of quantification) for second
derivative  spectra  were  found  to  be  9.7µg/ml  and29.74µg/ml.  The  correlation
coefficient value was found to be 0.9989. The purity was found to be 98%.23
 The present research was losartan potassium is an angiotensin II receptor antagonist
with  an  oral  bioavailability  of  only 33% due  to  extensive  first  pass  metabolism.
Mucoadhesive buccal films of losartan potassium were prepared using hydroxypropyl
methyl cellulose (HPMC) and retardant polymers ethyl cellulose or eudragit RS 100.
Ex vivo permeation studies of  losartan potassium solution through porcine buccal
mucosa  showed  90.2  % absorption  at  the  end  of  2  h.  The  mucoadhesive  force,
swelling  index  and  tensile  strength  was  shown  higher  for  those  formulations
containing higher percentage of HPMC. Ex vivo permeation studies through porcine
buccal mucosa indicate that films containing higher percentage of HPMC it showed
slower permeation of the drug for 6-7 hours.24
 The  present  work  aims  to  investing  the  possibility  of  sustaining  the  Losartan
potassium  release  from  matrix  tablet,  prepared  by  hydrophilic  and  hydrophobic
polymer. The mechanism of drug release was diffusion coupled with erosion. It can
be concluded that the polymer plays a major role in the design of sustained release
matrix tablet. The study reveals that the release of drug is low when the matrix tablet
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contained hydrophilic  and  hydrophobic  polymers  as  a  combination than the other
matrices  and  also  shows  anomalous  (non-fickian)  diffusion  kinetics.  Hence,  it  is
clearly manifest the necessity of combining different classes of polymer is to get an
acceptable pharmacokinetic profile in the fluctuating in vivo environment.25
 The present study was to formulate the buccal tablets of losartan potassium by using
of  carbopol  934P and  either  sodium  CMC,  HPMC  K4M  or  sodium  alginate  in
different  ratios.  The  buccal  tablets  were  subjected  for  evaluation  of  various
physicochemical properties. In vitro drug release studies were carried out using flow
thru cell. Stability studies were carried out at different conditions for two months. The
results of all physicochemical parameters of all batches were satisfactory and comply
with  theoretically  expected  values.  Group  III  formulation  was  shown  highest
percentage of drug release in  In  vitro  release studies.  Stability studies indicate no
significant changes with respect to surface pH, bioadhesive strength and drug content
at the end of two months.26
 The aim of the current study was to design oral controlled release matrix tablets of
losartan potassium. Tablets were prepared by direct compression method by using of
carbopol 934P and HPMC K 100M and evaluated for all physicochemical parameters.
In vitro release studies were conducted in phosphate buffer pH 6.8 for 24 hours. The
release profiles of losartan potassium from all the formulations (except F2, F3, and F8
which  showed  first  order  release)  are  close  to  zero  order  and  follow  diffusion
dependent  release.  Irrespective  of  the  polymer  type  and  its  concentration,  the
prepared hydrophilic matrix tablets showed non-fickian release, the values of release
exponent (n) are in between 0.584 and 0.8692.27
 The  purpose  of  the  present  study was  to  develop  a  buccoadhesive  drug  delivery
system  of  metoprolol  tartrate  (MT)  using  combination  of  natural  polymers.  The
29
tablets of MT were prepared by using semisynthetic polymer such as sodium carboxy
methyl cellulose and natural polymers such as gum karaya, xanthan gum and locust
bean gum. Ethyl cellulose used as an impermeable backing layer. Buccal tablets were
evaluated by different parameters such as hardness, ex vivo mucoadhesive strength, in
vitro  drug release and  ex vivo  drug permeation.  Results revealed that  formulation
containing combination of xanthan gum and locust bean gum in 2:1 ratio exhibited
complete drug release in 45 mins but poor drug permeation.28
 The present study was to develop a buccoadhesive drug delivery system of Insulin
using natural polymer locust bean gum. As insulin is a peptide drug, its delivery via
the  buccal  oral  cavity  has  several  therapeutic  advantages.  Locust  bean  gum is  a
mucoadhesive  polymer.  It  is  useful  as  a  stabilizer,  adsorbent  and  demulscent
therapeutically.  Mucoadhesive  buccal  tablets  of  insulin  are  prepared  by  direct
compression  method.  Buccal  tablets  are  evaluated  by  certain  parameters  like
dissolution,  in  vitro  bioadhesion  study,  drug  permeation study and  in  vivo  study.
Results  revealed that  the tablet  containing 5mg locust  bean gum and 4 mg PEG,
DME500 as an ideal formulation for mucoadhesive buccal delivery of insulin.29
 The current study was to design gastroretentive mucoadhesive theophylline tablets
and to optimize with naturals gums and their combinations. Tablets of theophylline
were  prepared  using  direct  compression  method  and  were  evaluated  for  different
physicochemical parameters. Different types of natural gums such as locustbean gum,
Carrageenan  gum,  natural  polymer  like  Chitosan and  synthetic  polymer  Carbopol
were used. Out of which the formulation with the combination of locust bean gum
and Chitosan (4.5:3) showed greater mucoadhesive strength, good swelling and  in
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vitro  drug release than using a single gum, other gum combinations and synthetic
polymer.30
 The present  study was  to  develop  hydrophilic  polymer  and  hydrophobic  polymer
based matrix Losartan potassium sustained release tablet which can release the drug
up to time of 24 hrs in predetermined rate. Formulation of Losartan potassium matrix
tablet was prepared by the polymer combination in order to get required theoretical
release  profile.  Influence  of  hydrophilic  and  hydrophobic  polymer  on  Losartan
potassium was studied. Administration of LP in a sustained release dosage would be
more desirable for antihypertensive effects by maintaining the plasma concentrations
of the drug well above the therapeutic concentration.31
 In  this  study,  a  new  dosage  form  was  developed  by  using  carbopol  934P  and
hydroxypropylmethylcellulose (HPMC K4M) as  bioadhesive polymers in different
ratios. The mucoadhesive strength was evaluated by detachment force measurement
from porcine  vaginal  mucosal  membrane.  The  formulations  were  tested  for  their
swelling behavior using agar gel plate. The swelling index increased with an increase
in the content of HPMC. In vitro and in situ release studies were also carried out
using porcine vaginal mucus membrane.32
 In the present work was to develop the mucoadhesive tablet of diclofenac by using
Aegle marmelos fruit gum as a binder. The preliminary evaluation of Aegle marmelos
gum showed that bulk density 0.42 ± 0.2 g/cm3, tapped density 0.45 ± 0.3 g/cm3 and
angle  of  repose  290 ±  0.15.  The  six  tablet  formulations  were  prepared  by direct
compression method. Tablets were subjected for evaluation of all physicochemical
parameters. Formulation was studied for drug additive interaction (FTIR). F4 is found
to be optimized formulation.  The  in-vitro  drug release of  F4 formulation exhibits
complete release of Diclofenac Sodium with non fiction first order release kinetic.33
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 The aim of study was to prepare and characterize buccoadhesive tablets of Metoprolol
tartrate by using carbopol 934, sodium alginate and HPMC K4M in combination. The
prepared tablets were evaluated for  physicochemical  parameters  such as hardness,
thickness, weight variation, surface pH, Ex‐vivo residence time, bioadhesive strength
and in vitro drug release. In vitro, bioadhesive strength and in vitro release studies
showed that formulation F8 containing 1:1.25 ratio of drug and polymer combination
showed optimum bioadhesive and exhibited optimum drug release (77.33±0.23).34
 The purpose of the study was to formulate and evaluate mucoadhesive bi-layer buccal
tablets  of  propranolol  hydrochloride  by  using  the  bioadhesive  polymers  such  as
sodium alginate  and  carbopol  971 P along with  ethyl  cellulose.  The  tablets  were
evaluated for all physicochemical parameters. The swelling index was proportional to
sodium alginate content and inversely proportional to carbopol 971 P content. The
surface pH of all tablets was found to be satisfactory, close to neutral pH; hence, no
irritation would observe with these tablets. The mechanism of drug release was found
to be zero-order kinetics.35
 The present study was to formulate and evaluate the bioadhesive buccal tablets of
tizanidine  hydrochloride.  The  tablets  were  prepared  by  direct  compression  using
bioadhesive  polymers  such  as  hydroxylpropyl  methylcellulose,  sodium
carboxymethyl cellulose alone, and a combination of these two polymers. To improve
the  permeation  of  drug,  different  permeation  enhancers  like  beta-cyclodextrin
hydroxypropyl beta-cyclodextrin are added to the formulations. Bioadhesion strength,
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ex  vivo  residence  time,  swelling,  and  in  vitro  dissolution  studies  and  ex  vivo
permeation studies were performed. In vitro release of optimized bioadhesive buccal
tablet was found to be non-Fickian.36
 The  present  work  was  to  formulate  the  buccal  tablets  of  poorly  soluble  drug
carvedilol. Drug-Methyl-β-Cyclodextrin complex was prepared by kneading method.
Dissolution rate of complex was compared with plain drug and physical mixture. The
complex was incorporated into buccal tablet. The buccal tablets were evaluated for
drug release, mucoadhesive strength and ex-vivo permeability. The complex showed
complete release as compared to  32.8% and 42.7% from plain  drug and physical
mixture respectively in 60min. Thus it can be concluded that buccal tablet containing
complexed CAR would have improvement in bioavailability.37
 In  present  investigation  an  attempt  was  made  to  formulate  and  evaluate
buccoadhesive tablets of Labetalol hydrochloride by using xanthan gum. Prepared
buccal tablets were comparatively evaluated for the surface pH, swelling index, bio-
adhesive  strength,  in-vivo  residence  time.  In  vitro  drug  release  rate  of  Labetalol
hydrochloride prepared from this material was studied in phosphate buffer of pH 6.8
containing 0.2% sodium lauryl  sulphate at 37±0.50c. Drug release from the tablets
followed fickian diffusion.38
 The  present  investigation  concerns  the  development  of  Buccoadhesive  tablets  of
Verapamil  Hydrochloride.  The  Buccal  tablets  were  formulated  using  four
mucoadhesive  polymers  namely,  Carbopol  934  P,  HPMC  K4M,  Hydroxy  ethyl
cellulose  and  Sodium  corboxymethylcellulose.  The  tablets  were  carried  out  the
weight  variation,  content  uniformity,  swelling index,  Bioadhesive  strength  and  in
vitro drug release. The cumulative % of drug release of formulation F6 was 97.01. In-
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vitro releases of F6 was found to be diffusion controlled and followed zero order
kinetics.39
 The present study was to prepare the salbutamol  sulphate buccal  tablets by using
HPMC K4M (Hydroxypropyl Methyl Cellulose) & EC (Ethyl Cellulose) in different
ratios 1:1, 1:2 & 2:1. The tablets were evaluated for all physicochemical parameters.
Swelling index of batches  containing more HPMC K4M was greater than that  of
contain less HPMC K4M. In vitro bioadhesive strength studies showed that tablets
containing more HPMC K4M were great bioadhesive in nature. The maximum in-
vitro release observed in formulation HE1. (1:1 ratio) and the kinetics studies shows
that release follows peppas model.40
 The aim of the work was to formulate the buccoadhesive morphine sulphate tablets
by using hydroxy propyl methyl cellulose (HPMC) with corbomer (CP).The release
behavior of systems containing 30 mg of morphine sulfate and various amounts of the
two polymers  was found to be non-Fickian.  The adhesive force was significantly
affected by the mixing ratio of HPMC and CP in the tablet, and the weakest adhesion
force was observed at the ratio of 1:1(HPMC: CP).41
 The  present  study  involves  the  formulation  and  evaluation  of  buccal  tablets  of
glipizide. The tablets were prepared by direct compression method using bioadhesive
polymers  like  Carbopol  974P,  Methocel  K4M  and  Methocel  K15M  in  different
concentrations. The modified in vitro assembly was used to measure the bioadhesive
strength of tablets with fresh porcine buccal mucosa as model tissue. The tablets were
evaluated for  in vitro  release in pH 6.8 phosphate buffer for 8 hr.  The optimized
formula followed non-fickian release mechanism with zero order kinetics.42
 The objective of this study was to extend the GI residence time of the dosage form
and  control  the  release  of  rosiglitazone  using  mucoadhesive  tablet  to  achieve
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controlled plasma. Direct compression method using simplex lattice design, followed
by optimization of the evaluation parameters was employed to get  final optimized
formulation. The optimized formulation showed a mucoadhesive strength >40 gm-f,
and a mucoadhesion time >12 hours with release profile closer to the target release
profile  and  followed  Non-Fickian  diffusion  mediated  release  of  rosiglitazone
maleate.43
4.  MATERIALS AND METHODOLOGY
DRUG PROFILE
LOSARTAN POTASSIUM45, 46
Structural formula
Chemical formula:
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2 ‐ butyl ‐ 4 ‐ chloro ‐ 1 ‐ [ p‐ (o ‐ 1 H ‐ tetrazol ‐ 5 ‐ ylphenyl) benzyl] imidazole – 5 ‐
methanol
Empirical formula: C22H22ClKN6O
Molecular weight:  461.01
Description: White or almost white powder.
Melting point: 105-110o
Solubility: It is freely soluble in water and soluble in alcohols.
Half life: 2.1 hr
Drug category: anti hypertensive
Mechanism of  action: Losartan  potassium is  an  angiotensin  II  receptor  antagonist.  It
suppresses  the  effects  of  angitensin  II  at  its  receptors,  thereby  blocking  the
renninangiotensin  system.The  rennin‐angiotensin  system  plays  a  crucial  role  in  the
control of blood pressure, and in particular it is felt to play crucial role in hypertension.
Losartan has been demonstrated to be superior to previous peptide receptor antagonists
and angiotensin converting enzyme (ACE) inhibitors because of its enhanced specificity,
selectively, and tolerability.
Pharmacokinetics:
Absorption
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Following  oral  administration,  losartan  is  well  absorbed  and  undergoes  first-pass
metabolism, forming an active carboxylic acid metabolite and other inactive metabolites.
The  systemic  bioavailability  of  losartan  tablets  is  approximately  33%.  Mean  peak
concentrations  of losartan and its  active  metabolite  are reached in  1  hour and in  3-4
hours, respectively.
Distribution
Both losartan  and  its  active  metabolite  are  99% bound to  plasma proteins, primarily
albumin. The volume of distribution of losartan is 34 litres
Elimination
Plasma  clearance  of  losartan  and  its  active  metabolite  is  about  600  ml/min  and  50
ml/min, respectively.  Renal clearance of losartan and its active metabolite is about 74
ml/min and 26 ml/min, respectively. When losartan is administered orally, about 4% of
the dose is excreted unchanged in the urine, and about 6% of the dose is excreted in the
urine as active metabolite. The pharmacokinetics of losartan and its active metabolite are
linear with oral losartan potassium doses up to 200 mg.
Dose: 25, 50 and 100mg.
Nervous system disorders:
Common: dizziness, vertigo
Uncommon: somnolence, headache, sleep disorders
Cardiac disorder:
Uncommon: palpitations, angina pectoris.
Vascular disorders:
Uncommon: symptomatic hypotension (especially in patients with intravascular volume
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depletion,  e.g.  patients  with  severe  heart  failure  or  under treatment  with  high  dose
diuretics), dose-related orthostatic effects, rash.
Gastrointestinal disorders:
Uncommon: abdominal pain, obstipation
General disorders and administration site conditions:
Uncommon: asthenia, fatigue, oedema
Marketed Brands: LOSAR, COZAAR
POLYMER PROFILE
LOCUST BEAN GUM47,
Synonyms :  Algaroba;  carob bean gum; carob flour; ceratonia gum; ceratonia siliqua;
ceratonia  siliqua  gum;  Cheshire  gum;  E410;  gomme  de  caroube;  locust  bean  gum;
Meyprofleur; St. John’s bread.
Chemical Name: Carob gum.
Empirical  Formula  and  Molecular  Weight:  Ceratonia  is  a  naturally  occurring  plant
material that consists chiefly of a high molecular weight hydrocolloidal polysaccharide,
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composed of D-galactose and D-mannose units combined through glycosidic linkages,
which  may  be  described  chemically  as  galactomannan.  The  molecular  weight  is
approximately 310 000.
Molecular Structure:
Functional  Category:  Controlled-release  vehicle;  stabilizing  agent;  suspending  agent;
tablet binder; viscosity-increasing agent.
Applications in Pharmaceutical Formulation or Technology:
Ceratonia  is  widely  used  as  a  binder,  thickening  agent,  and  stabilizing  agent  in  the
cosmetics and food industry.  In  foods,  0.15–0.75% is used.  Therapeutically,  ceratonia
mucilage is used orally in adults and children to regulate intestinal Function. Ceratonia
has also been used as a tablet binder and is used in oral controlled-release drug delivery
systems approved in Europe and the USA.
Description: Ceratonia  occurs  as  a  yellow-green  or  white  colored  powder.  Although
odorless and tasteless in the dry powder form, ceratonia acquires a leguminous taste when
boiled in water.
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Viscosity (dynamic): 1200–2500 mPa s (1200–2500 cP) for a 1% w/v aqueous dispersion
at 258C. Viscosity is unaffected by pH within the range pH 3–11. Viscosity is increased
by heating: if heated to 958C then cooled, practically clear solutions may be obtained that
are more viscous than prior to heating.
Stability and Storage Conditions :  The bulk material should be stored in a well-closed
container in a cool, dry place. Ceratonia loses not more than 15% of its weight on drying.
Incompatibilities:
The viscosity of xanthan gum solutions is increased in the presence of ceratonia. This
interaction is used synergistically in controlled-release drug delivery systems.
HYDROXYPROPYLMETHYLCELLULOSE K4M:47
Non-proprietary names:
BP: Hypromellose
JP: Hydroxypropylmethylcellulose
PhEur: Hypromellosum
USP: Hypromellose
Synonyms
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Benecel  MHPC;  E464;  hydroxypropyl  methylcellulose;  HPMC;  Methocel;
methylcellulose  propylene  glycol  ether;  methyl  hydroxypropylcellulose;  Metolose;
Tylopur.
STRUCTURAL FORMULA
Where R is H, CH3, or CH3CH(OH)CH2
Chemical Name and CAS Registry Number
Cellulose hydroxypropyl methyl ether [9004-65-3]
Molecular weight
Approximately 10 000 –1 5,00 000.
Description
Hypromellose  is  an  odorless  and  tasteless,  white  or  creamywhite  fibrous  or  granular
powder.
Functional Category
Coating agent;  film-former;  rate-controlling polymer  for  sustained  release;  stabilizing
agent; suspending agent; tablet binder; viscosity-increasing agent
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Melting point: browns at 190–2000 C; chars at 225–2308C.
Solubility:
Soluble  in  cold  water,  forming  a  viscous  colloidal  solution;  practically  insoluble  in
chloroform,  ethanol  (95%),  and  ether,  but  soluble  in  mixtures  of  ethanol  and
dichloromethane, mixtures of methanol and chloromethane, and mixtures of water and
alcohol
pH = 5.5–8.0 for a 1% w/w aqueous solution
Viscosity: 4000 mPa.
Stability and Storage Conditions
Hypromellose  powder  is  a  stable  material,  although  it  is  hygroscopic  after  drying.
Hypromellose powder should be stored in a well-closed container, in a cool, dry place.
Safety
Hypromellose  is  generally  regarded  as  a  nontoxic  and  nonirritant  material,  although
excessive oral consumption may have a laxative effect.
MAGNESIUM STEARATE47
BP: Magnesium stearate
JP: Magnesium stearate
PhEur: Magnesii stearas
USPNF: Magnesium stearate
Synonyms
Magnesium octa decanoate;  octa decanoic acid, magnesium salt; stearic acid, magnesium
salt.
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Structural Formula
[CH3(CH2)16COO]2Mg
Chemical Name and CAS Registry Number
Octadecanoic acid magnesium salt [557-04-0]
Molecular Weight: 591.34.
Description
Magnesium stearate is a very fine, light white, precipitated or milled, impalpable powder
of low bulk density, having a faint odor of stearic acid and a characteristic taste. The
powder is greasy to the touch and readily adheres to the skin.
Functional Category
Tablet and capsule lubricant
Applications in Pharmaceutical Formulation or Technology
Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical formulations.
It  is primarily used as a lubricant  in capsule and tablet manufacture at concentrations
between 0.25% and 5.0% w/w. It is also used in barrier creams
Melting range:
117–1508C (commercial samples); 126–1308C (high purity magnesium stearate).
Solubility:
practically insoluble in ethanol, ethanol (95%), ether and water; slightly soluble in warm
benzene and warm ethanol (95%).
Stability and Storage Conditions
Magnesium stearate is stable and should be stored in a wellclosed container in a cool, dry
place.
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Safety
Magnesium  stearate  is  widely  used  as  a  pharmaceutical  excipient  and  is  generally
regarded as being nontoxic following oral administration. However, oral consumption of
large quantities may produce a laxative effect or mucosal irritation.
TALC47
Nonproprietary Names
BP: Purified talc
JP: Talc
PhEur: Talcum
USP: Talc
Synonyms
Altalc;  E553b;  hydrous  magnesium  calcium  silicate;  hydrous  magnesium  silicate;
Luzenac Pharma;  magnesium hydrogen metasilicate;  Magsil  Osmanthus;  Magsil  Star;
powdered talc; purified French chalk; Purtalc; soapstone; steatite; Superiore.
Chemical Name and CAS Registry Number
Talc [14807-96-6]
Description
Talc is a very fine, white to grayish-white, odorless, impalpable,  unctuous, crystalline
powder. It adheres readily to the skin and is soft to the touch and free from grittiness.
Functional Category
Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule lubricant.
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Solubility:
Practically insoluble in dilute acids and alkalis, organic solvents, and water.
Safety
Talc is used mainly in tablet and capsule formulations. Talc is not absorbed systemically
following oral ingestion and is therefore regarded as an essentially nontoxic material.
However However, intranasal or intravenous abuse of products containing talc can cause
granulomas in body tissues, particularly the lungs.(16–18) Contamination of wounds or
body cavities with talc may also cause granulomas; therefore, it should not be used to
dust surgical gloves. Inhalation of talc causes irritation and may cause severe respiratory
distress in infants
ETHYL CELLULOSE47
Synonyms: Aquacoat ECD, Aqualon E 462, Ethocel
Chemical name: Cellulose ethyl ether
Molecular weight: Ranges from 0.98 × 105 to 4.10 × 105
Functional category:
Coating agent,  flavoring fixative, tablet binder, tablet filler, viscosity-increasing agent.
Application in pharmaceutical formulation or technology:
45
It is widely used in oral and topical pharmaceutical formulation. Ethyl cellulose coatings
are used to modify the release of a drug, to mask the unpleasant taste, or to improve the
stability of a formulation.
Description:
It is a tasteless, free- flowing, white to light tan colored powder
Solubility:
It is practically insoluble in glycerin, propylene glycol and water. It is freely soluble in
chloroform, ethanol, ethyl acetate, methanol and toluene.
Stability and storage condition:
It  is  a  stable,  slightly hygroscopic  material.  It  should be stored at  a  temperature  not
exceeding 32 °C in a dry area.
Specific gravity: 1.12- 1.15 g/cm3
Safety: It is not recommended for parenteral products; it may be harmful to kidneys.
5. RESULTS
5.1 Preformulation Studies:
5.1.1 Organoleptic Properties:
a) Colour: A small quantity of Losartan potassium powder was taken in butter paper and
viewed in well-illuminated place.
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b) Taste and odour: Very less quantity of Losartan potassium was used to get taste with
the help of tongue as well as smelled to get the odour.
Test Specification/limits Observations
Colour White White
Taste Bitter Bitter
Odour Odourless Odourless
Table 7: Organoleptic Properties for Losartan potassium
5.1.2. Standard plot of Losartan potassium in methanol:
Si no. Concentration (µg/ml)
Absorbance
Mean± SD
0 0 0
1 4 0.144 ± 0.026
2 8 0.262 ± 0.010
3 12 0.405 ± 0.045
4 16 0.506 ± 0.045
5 20 0.628 ± 0.055
All values are mean ± SD, n =3.
Table 8: Standard graph data of Losartan potassium in methanol at 234 nm
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Figure 5: Standard graph of Losartan potassium in methanol
5.1.3. Fourier Transform Infrared spectroscopy:
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Figure 6: FT-IR Spectra of Losartan potassium
Figure 7: FT-IR spectra of Losartan potassium+ locustbean gum.
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Figure 8: FT-IR spectra of Losartan potassium+ HPMC K4M
Figure 9: FT-IR spectra of Losartan potassium+ Locustbean gum+ HPMC K4M
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Pure losartan potassium
Functional group Range Observed range in pure drug
OH 1270-1160 1257.06
1,4  di  substituted
phenyl ring
850-800 842.51
1,6 substituted phenyl
ring
780-720 788.43
C-Cl 850-550 668.61
C-C arometic 1500-1400 1457.04
NH 910-665 762.31
Table 9: FTIR Spectral data of Losartan potassium
Name of pure
drug
Standard
value  of
drug(cm-1)
Observed value
of
LOCUSTBEA
N  GUM  with
drug(cm-1)
Observed  value
of  KPMC K4M
with drug(cm-1)
Observed
value  of
polymer
combination
with drug(cm-
1)
1160 -1270 1256.57 1257.05 1256.94
800-850 839.15 842.28 840.31
720-780 788.12 788.76 788.51
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Losartan
potassium
550-850 669.68 668.15 668.59
1500-1400 1458.50 1457.07 1457.10
910-665 762.21 762.46 762.31
Table 10: interpretation for IR spectra of Losartan potassium and polymers
5.1.4 Differential Scanning Calorimetry (DSC):
Figure 10: DSC of losatran potassium
Figure 11: DSC of losartan potassium and HPMC K4M
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Figure 12: DSC of losartan potassium+ locust bean gum
5.2. Precompression parameters for Losartan potassium
5.2.1. Bulk density, tapped density and compressibility index:
BATCH
CODE
BULK
DENSIY
(GM/CM3
)
TAPPED
DENSITY
(GM/CM3)
COMPRESSI
BILITY
INDEX (%)
HAUSNE
R’S RATIO
ANGLE OF
REPOSE (Θ)
F1 0.443 0.544 18.6 1.23 31.1
F2 0.457 0.552 17.4 1.21 28.5
F3 0.443 0.539 17.9 1.22 29.1
F4 0.453 0.541 16.28 1.19 29.88
F5 0.459 0.538 14.8 1.18 26.8
F6 0.422 0.549 21.4 1.27 31.6
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F7 0.459 0.559 17.8 1.22 30.52
F8 0.433 0.513 15.4 1.18 29.62
F9 0.437 0.526 16.76 1.21 28.6
Table 11: Data of bulk density, tapped density, compressibility index, Hauser’s ratio and
angle of repose.
5.2.2. Evaluation of buccal tablets
A. Physicochemical parameters
Formulation
Hardness
kg/cm2
Thickness
(mm)
Weight
Variation (mg)
Friability
(% loss)
F1 3.1 ± 0.42 3.8 ± 0.28 194.2 ± 0.81 0.51 ± 0.27
F2 5.0 ± 0.18 4.2 ± 0.04 235.9 ± 1.62 0.31 ± 0.06
F3 4.2 ± 0.09 4.1 ± 0.15 234.8 ± 0.77 0.29 ± 0.24
F4 7.8 ± 0.26 4.8 ± 0.91 285.3 ± 4.26 0.11 ± 0.43
F5 3.2 ± 0.84 4.0 ± 0.52 209.8 ± 0.98 0.38 ± 0.37
F6 6.0 ± 0.12 4.5 ± 0.22 268.1 ± 1.45 0.25 ± 0.08
F7 3.5 ± 1.53 3.9 ± 0.08 203.9 ± 3.11 0.42 ± 0.09
F8 6.5 ± 2.41 4.6 ± 0.05 274.2 ± 2.81 0.22 ± 0.18
F9 6.0 ± 0.35 4.2 ± 0.51 239.6 ± 1.86 0.28 ± 0.24
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All values are mean ± SD, n =3.
Table 12: Physicochemical parameters of developed buccal tablets
B. Drug Content uniformity:
Formulation Amount  of  drug
present (mg)
% Drug content
F1 98.45±0.061 98.45±0.061
F2 98.06±0.031 98.06±0.031
F3 97.10±0.026 97.10±0.026
F4 98.84±0.035 98.84±0.035
F5 99.29±0.025 99.29±0.025
F6 97.42±0.025 97.42±0.025
F7 96.45±0.035 96.45±0.035
F8 97.29±0.042 97.29±0.042
F9 98.71±0.028 98.71±0.028
All values are mean ± SD, n =3.
Table 13: Amount of drug present and % drug content
C. % Swelling index of the developed buccal tablets
% SWELLING INDEX
Formulation 2h 4h 6h 8h 10h
F1 56 69 75 88 102
F2 85.4 98 110 120 142
F3 78.3 90.2 99 115 120.6
F4 85.2 114.5 125.8 134.4 151
F5 73.7 90 95.6 105 114.6
F6 82 106 118 136 149
F7 61.4 81.5 91.6 100.6 112
F8 57.4 84.4 87 98 121
F9 82.4 103 112 123 144
Table 14: % Swelling index of developed formulations
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Figure 13: % swelling index graph of 9 formulations
D. Bioadhesive properties
Formulation
mucoadhesive
time (h)
Bioadhesion
strength (gm)
Force of adhesion
(N) Surface pH
F1 8.4 20.6 ± 0.05 0.202 ± 0.24 5.6 ± 0.04
F2 >10 30.2 ± 0.24 0.296 ± 0.66 6.1 ± 0.42
F3 9.2 21.6 ± 0.11 0.211 ± 0.047 6.8 ± 0.09
F4 >10 29.1 ± 0.42 0.285 ± 0.52 7.0 ± 0.06
F5 7.2 18.9 ± 0.08 0.185 ± 0.051 5.8 ± 0.52
F6 >10 31.5 ± 0.14 0.309 ± 0.81 6.4 ± 0.08
F7 9.45 25.4 ± 0.37 0.249 ±0.62 5.6 ± 0.05
F8 >10 27.1 ± 0.19 0.266 ± 0.06 6.8 ± 0.11
F9 >10 26.5 ± 0.66 0.259 ± 0.14 6.2 ± 0.22
All values are mean ± SD, n =3.
Table 15: Bioadhesive properties of developed buccal tablets
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Figure 14: Mucoadhesive strenth of developed buccal tablets
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Figure 15: Force of adhesion of developed buccal tablets
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Figure 16: Surface pH of 9 formulations
E. In-vitro dissolution studies.
Time (h)
% Cumulative Drug Release
F1 F2 F3
0 0 0 0
0.5 25.25±0.08 21.48±0.055 23.22±0.065
1 35.26±0.15 25.96±0.065 34.38±0.124
2 46.49±0.06 31.91±0.082 42.71±0.092
3 60.69±0.11 35.57±0.124 49.91±0.11
4 69.15±0.14 43.89±0.154 58.02±0.064
5 77.39±0.04 52.84±0.086 66.18±0.082
6 86.21±0.16 58.07±0.064 72.63±0.035
7 93.06±0.12 62.74±0.063 79.42±0.0258
8 96.47±0.076 72.37±0162 85.37±0.124
9 87.57±0.115 89.31±0.16
10 94.42±0.214 93.28±0.066
All values are mean ± SD, n =3
Table 16: In-vitro drug release data for formulations F1 - F3
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Figure 17: % CDR of Formulations F1-F3
Table 17: In-vitro drug release data for formulations F4 – F6
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Figure 18: % CDR of Formulations F4-F6
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Time (h) % Cumulative Drug Release
F7 F8 F9
0 0 0 0
0.5 22.06±0.24 18±0.061 20.91±0.042
1 30.32±0.051 23.06±0.025 26.07±0.38
2 40.94±0.24 27.23±0.038 33.36±0.25
3 47.55±0.25 34.64±0.15 40.51±0.16
4 55.65±0.55 40.92±0.42 45.08±0.035
5 68.15±0.081 47.53±0.091 53.46±0.061
6 79.55±0.12 54.47±0.12 58.69±0.028
7 87.82±0.18 60.86±0.062 69.46±0.25
8 95.56±0.62 70.19±0.034 77.090±0.062
9 77.54±0.024 85.35±0.13
10 87.83±0.062 95.97±0.095
All values are mean ± SD, n =3
Table 18: In-vitro drug release data for formulations F7 – F9
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Figure 19: % CDR of Formulations F7-F9
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Figure 20: Comparison of zero order of in vitro drug release F1-F4
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Figure 21: comparison of zero order of in vitro drug release F5-F9
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Figure 22: comparison of first order of in vitro drug release F1-F4
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Figure 23: comparison of first order of in vitro drug release F5-F9
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Figure 24: comparison of Higuchi model of in vitro drug release F1-F4
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Figure 25: comparison of Higuchi model of in vitro drug release F5-F9
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Figure 26: comparison of Korsmeyers-peppas equation of in vitro drug release F1-F4
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Figure 27: comparison of Korsmeyers-peppas equation of in vitro drug release F5-F9
5.3. OPTIMIZATION
The runs or formulations, which are designed based on central composite design,
are evaluated for the response. The response values are subjected to multiple regression
analysis to find out the relationship between the factors used and the response values
obtained. The response values subjected for this analysis are;
1. Percentage of Drug Release at 1st hour
2. Percentage of Drug Release at 8st hour.
3. n value
4. Mucoadhesive strength
5. Hardness
The duration of above responses were chosen for the analysis of the following
relationship:
1. To study the effect of amount of Locustbean gum
2. To study the effect of amount of HPMC K4M.
3. To study the combined effect of Locustbean gum, HPMC K4 M.
The multiple regression analysis was done using design expert 8.0.4.1 software,
which is specially meant for this optimization process. The results of this analysis are
presented in the table 20.
Using the regression coefficient of the factors, the polynomial equation for the response
is constructed.  Only significantly,  contributing factors are considered for the equation
generation.
Run Locustbean
gum
HPMC
K4M
%CD
R   at
1st h
%CDR
at 8th h
n value Mucoadhesi
ve strenth
gm/cm2
hardnes
gm/cm2
1 18.00 20.00 35.27 97.93 0.495 20 3.1
2 60.00 20.00 25.96 72.37 0.49 30 5
3 18.00 70.00 34.39 85.37 0.452 21 4
4 60.00 70.00 18.09 68.32 0.56 29 8
5 9.30 45.00 28.11 91.14 0.529 18 3.2
6 68.70 45.00 26.54 78.03 0.501 31 6
7 39.00 9.64 30.32 97.59 0.527 25.4 3
8 39.00 80.36 23.06 70.19 0.525 27.1 6.5
9 39.00 45.00 26.07 77.09 0.502 26.5 6
Table 20: Design and Summary Response Data
Response 1: % cumulative drugrelease at 1st houre
Source
Sum  of
Squares
DF Mean Square F Value
p-value
Prob >F
Model 142.02 2 71.01 4.86 0.0557
A 96.82 1 96.82 6.62 0.0422
B 45.21 1 45.21 3.09 0.1292
Residual 87.74 6 14.62 - -
Cor Total 229.76 8 - - -
Table 21: ANOVA for Response Surface Linear Model
Factor Coefficient STANDARD DF
Estimate
A-locust bean gum -3.48 1
B-hpmc k4m -2.38 1
Table 22: Estimated regression coefficient
Final Equation in Terms of Coded Factors:
DRUG RELEASE AT 1 h= +27.53- 3.48* A-2.38* B
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Figure 28: Correlation between actual and predicted values for drug release at 1 h (R1)
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  A: locust bean gum    B: hpmc k4m  
Figure  29:  3-D graph  showing  effect  of  Locustbean  gum and  HPMC K4M on  drug
release at 1 h (R1)
Response 2: % cumulative drug release at 8 th houre
Source
Sum  of
Squares
DF Mean Square F Value
p-value
Prob >F
Model 850.50 2 425.25 12.73 0.0069
A 467.42 1 467.42 13.99 0.0096
B 383.08 1 383.08 11.47 0.0147
Residual 200.43 6 33.40 - -
Cor Total 1050.93 8 - - -
Table 23: ANOVA for Response Surface Linear Model
Factor
Coefficient
Estimate
STANDARD DF
A-locust bean gum -7.64 1
B-hpmc k4m -6.92 1
Table 24: Estimated regression coefficient
Final Equation in Terms of Coded Factors:
DRUG RELEASE AT 8 h = +82.00-7.64  * A-6.92* B
Design-Exper t® Soft ware
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Figure 30: Correlation between actual and predicted values for drug release at 8 h (R2)
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  A: locust bean gum  
  B: hpmc k4m  
Figure  31:  3-D graph  showing  effect  of  Locustbean  gum and  HPMC K4M on  drug
release at 8 h (R2)
Response 3: n value
Source
Sum  of
Squares
DF Mean Square F Value
p-value
Prob >F
Model 3.768E-003 3 1.256E-003 1.68 0.2848
A 5.025E-004 1 5.025E-004 0.67 0.4493
B 7.303E-005 1 7.303E-005 0.098 0.7671
AB3 3.192E-003 1 3.192E-003 4.28 0.0935
Residual 3.732E-003 5 7.464E-004 - -
Cor Total 7.500E-003 8 - - -
Table 25: ANOVA for Response Surface 2FI Model
Factor
Coefficient
Estimate
STANDARD DF
A-locust bean gum 7.925E-003 1
B-hpmc k4m 3.021E-003 1
AB 0.028 1
Table 26: Estimated regression coefficient
Final Equation in Terms of Coded Factors:
n  value:  +0.51+7.925E-003  *  A  +3.021E-003  *  B+0.028*  A  *  B
Desi gn-Exper t® S oft ware
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n:
0. 56
0. 452
Actual
P
re
d
ic
te
d
Predicted vs. Actual
0.44
0.46
0.48
0.50
0.52
0.54
0.56
0.58
0.44 0.46 0.48 0.50 0.52 0.54 0.56 0.58
Figure 32: Correlation between actual and predicted values for n value (R3)
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Figure 33: 3-D graph showing effect of Locustbean gum and HPMC K4M on n value
(R3)
Response 4: Mucoadhesive strength
Source
Sum  of
Squares
DF Mean Square F Value
p-value
Prob >F
Model 166.20 2 83.10 75.36 < 0.0001
A 165.48 1 165.48 150.07 < 0.0001
B 0.72 1 0.72 0.66 0.4492
Residual 6.62 6 1.10
Cor Total 172.82 8
Table 27: ANOVA for Response Surface Linear Model
Factor
Coefficient
Estimate
STANDARD DF
A-locust bean gum 4.55 1
B-hpmc k4m 0.30 1
Table 28: estimated regression coefficient
Final Equation in Terms of Coded Factors:
Mucoadhesive strenth = +25.33+ 4.55 *A+0.30 * B
Desi gn-Expert ® Soft ware
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Figure 34: Correlation between actual  and predicted values  for Mucoadhesive strenth
(R4)
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  A: locust bean gum  
  B: hpmc k4m  
Figure  35:  3-D  graph  showing  effect  of  Locustbean  gum  and  HPMC  K4M  on
mucoadhesive strenth (R4)
Response 5: hardness
Source
Sum  of
Squares
DF Mean Square F Value
p-value
Prob >F
Model 21.94 2 10.97 20.87 0.0020
A 12.15 1 12.15 23.12 0.0030
B 9.79 1 9.79 18.62 0.0050
Residual 3.15 6 0.53 - -
Cor Total 25.10 8 - - -
Table 29: ANOVA for Response Surface Linear Model
Factor
Coefficient
Estimate
STANDARD DF
A-locust bean gum 1.23 1
B-hpmc k4m 1.11 1
Table 30: Estimated regression coefficient
Final Equation in Terms of Coded Factors:
hardness = +4.98+1.23 * A+1.11 * B
Desi gn-Exper t® Sof tware
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Figure 36: Correlation between actual and predicted values for hardness (R5)
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Figure 37: 3-D graph showing effect of Locustbean gum and HPMC K4M on hardness
(R5)
5.3.1. Optimized formula
*INGREDIENTS R
Losartan potassium 100
Locustbean gum 46.59
HPMC K4M 55.45
Mannitol 15
Magnesium stearate 5
Talc 3
Aerosil 2
Ethyl cellulose 30
TOTAL 257.04
Table 31: Composition of the optimized formula.
5.3.2. Comparison between the experimental (E) and predicted (P) values
Optimized
Formulatio
n
Dependable Variables
% CDR at
1h
% CDR at
8h
n Mucoadhesive
strength g/cm2
Hardness
Kg/cm2
Predicted 25.27 76.35 0.52 27.11 5.89
Experiment 25.08 77.2 0.521 27 5.9
Table 32: Comparison between the experimental (E) and predicted (P) values for the most
probable optimal formulation
5.3.3. Results for optimization batch
Sr. No. Parameters Results
1. Appearance Good
2. Hardness 5.9 kg/cm2
3. Friability 0.21
4. Drug content 99.03 %
5. Ex-  vivo  mucoadhesion
strength
27 g/cm2
6. Ex- vivo mucoadhesion time 10.50 h
7. Surface pH 6.2
8. % Swelling index at 10 h 145.4
9. In- vitro drug release 97.30
Table 33: Results for optimization batch
Drug release kinetic studies for optimized formula
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Figure 38: zero order of invitro release for optimized formula
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Figure 39: First order of invitro release for optimized formula
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Figure 40: Higuchi of invitro release for optimized formula
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Figure 41: Korsmeyers-peppas equation of in vitro drug release for optimized formula
5.4: Stability studies
Time Hardness
(Kg/cm2)
Friabilit
y (%)
Drug
content (%)
% CDR at
10 h
Mucoadh
esive
strength
Initial 5.91±0.22
0.21±0.4
2 99.03±0.62
97.30±0.6
1
27±0.12
First
Month 5.9±0.82
0.22±0.5
2 99.0±0.12
97.12±0.0.
26
27.4±0.44
Second
Month
5.94±0.2
4 0.20±1.6 99.12±0.22
97.4±0.34 27.28±0.3
2
Third
Month
5.86±0.9
12
0.212±0.
88 98.92±1.05
97.06±0.2
4
27.06±1.0
Table 34: At ambient condition (25±2°C and relative humidity 60± 5%)
Time Hardness
(Kg/cm2)
Friabilit
y (%)
Drug
content (%)
% CDR at
10 h
Mucoadhe
sive
strength
Initial 5.91±0.32
0.21±0.0
8 99.03±0.21
97.31±0.1
5
27.2±0.21
First
Month
5.92±0.24 0.218±0.
42
99.0±0.21 97.42±0.0
8
27.18±0.2
1
Second
Month
5.932±0.2
2
0.208±0.
105 99.12±1.1
97.28±0.1
2
27.6±0.18
Third
Month
5.892±0.1
6 0.212±0.21
99.1±0.52 97.08±0.11 27.11±1.02
Table 35: At elevated temperature (40±2°C and relative humidity 75± 5%)
6. DISCUSSION
Mucoadhesive buccal drug delivery system is a promising tool for the drugs with low oral
bioavailability due  to  extensive first  pass  effect  and also this  route provides  an easy
termination of drug effect and it avoids the first pass metabolism. Losartan potassium is
the first orally active angeotensin II receptor antagonist with low oral bioavailability due
to extensive first pass metabolism.
In the present work, mucoadhesive buccal tablets of losartan potassium were prepared by
using locust bean gum with HPMC K4M by direct compression method.
6.1 Preformulation studies:
6.1.1. Identification:
The Losartan potassium was estimated using methanol solution and the calibration curve
was constructed in this solution at 243 nm as shown in table-8, figure-5. The method
obeys Beer-Lambert‘s law in the studied range of 4-20 mcg/ml with high r2 value of
>0.996 and low SD value suggested that method was reproducible and hence suitable
for estimation of losartan potassium.
6.1.2. FTIR Study:
Pure drug losartan potassium exhibited characteristics absorption bands which given in
table 9, the IR regions mentioned below:
The peak 1457.04 cm-1 may be due to C=C aromatic ring stretching 1257.06 cm-1 may be
due to OH bending 842.51 cm-1 may be due to1,4 di substituted phenyl ring 788.43 cm-1
may be due to 1,6 substituted phenyl ring 668.61 cm-1 peak due to the C-Cl group and
762.31 cm-1 peak due to the NH group.
The IR data of the formulation was compared with the standard spectrum of pure drug
losartan potassium and the characteristic peaks associated with specific functional groups
and  bonds  of  the  molecule  and  their  presence/absence  in  the  polymeric  carrier
(formulation)  were  noted.  The  IR  spectra  of  losartan  potassium with  combination  of
polymers are shown in table-10. The IR spectrum of the formulation showed that there is
no significant evidence for interaction between drug and the polymer. Peaks of both drug
as well as formulation were observed are same. So this clearly suggest that the drug has
not undergone any interaction with the polymer in the formulation, as there is no any shift
in the positions of the characteristic absorption bands of drug in the formulation.
Mucoadhesive buccal tablets of losartan potassium were prepared by direct compression
method  using  locust  bean  gum  in  varying  concentration  as  a  primary  polymer  and
combination with HPMC K4M in fixed amount. The optimized formulation of Losartan
potassium mucoadhesive buccal tablet is presented in Table-31. The total 9 formulation
are  prepared  and  weight  obtained  for  tablets  was  from 193-285 mg.  the  weights  are
shown in the table-4.
6.1.3 Differential Scanning Calorimetry (DSC):
In DSC studies melting peak appeared at 186.80⁰ C for losartan potassium. There was no
change in the melting point of binary mixture of losartan potassium and HPMC K4M and
losartan  potassium  and  locust  bean  gum  which  indicate  that  there  is  no  interaction
between drug and polymers.
6.2. EVALUATION PARAMETERS FOR LOSARTAN POTASSIUM:
6.2.1. Precompression parameters for Losartan potassium
In  the present study,  direct  compression method was adopted for  buccal  tablets.  The
data’s were shown in Table 11. The values for angle of repose were found in the range of
26.8° to 31.6°. Bulk densities and tapped densities of various formulations were found to
be in the range of 0.422 to 0.459 (gm/cm3) and 0.513 to 0.559 (gm/cm3) respectively.
Carr’s index of the prepared blends fall in the range of 14.8% to 21.4%. From the result it
was concluded that the powder blends had good flow properties and these can be used for
tablet manufacture.
6.2.2. Evaluation of buccal tablets
A. Physico-chemical evaluation of tablets:
Hardness:
The hardness of prepared mucoadhesive buccal tablets was from 3.1 to 7.8 kg/cm2 and
the data’s were shown in Table 12. The hardness is increased due to increasing weight of
the tablet. Also the hardness of the tablet was increased as the concentration of locust
bean gum and HPMC K4M were increased in each formulation.
Hardness R 5 = +4.98+1.23*A+1.11* B
The linear model is selected for this response with F-value 20.87 and p value is 0.0020
which indicates the model is significant. Both the factors  A, locust bean gum and factor
B, HPMC K4M increase the hardness of the buccal tablets.
Thickness, weight variation and Friability:
The average thickness of the all buccal tables ranges from 3.8 to 4.8 mm. The value of
percentage  variation  in  weight  and  friability  were  shown  in  the  table  12.  All  the
formulation values found to be within the limit of conventional oral tables stated in the
Indian pharmacopeia.
B. Drug Content uniformity:
Drug content uniformity study was carried out on the tablets of every batch and the data’s
were shown in the Table 13. The content uniformity of all the formulations was found to
be in the range of 96.45% to 99.29% which showed that there was uniform distribution of
the drug throughout the batch.
C. % Swelling index at 10 h:
The swelling study of prepared buccal tablets was performed in phosphate buffer pH 6.8
and the results are presented as percentage weight change with respect to time in Table 14
and in figure 13. The swelling behaviour of a bioadhesive system is an important property
for uniform and prolonged release of drug and bioadhesion. The swelling index of buccal
tablets were directly proportional to the concentration of the polymer,  as the polymer
concentration increases there was increase in the swelling index. The swelling of all the
tablets was increased as the time proceeds because the polymer gradually absorbs water
due to hydrophilicity of the polymer. The % swelling index was found 102 to 151. The F4
and F6 shown better swelling index compare to the other formulations, which shown 151
% and 149 % these formulations contains high concentrations of locust bean gum and
HPMC K4M. The locust bean gum and HPMC K4M both are increasing the swelling
effect for tablets. The locust bean gum showing more swelling effect (30) compare to
HPMC K4M because locust bean gum has more gelling capacity. The order of swelling
of polymeric tablets were F4>F6>F9>F2>F8>F3>F5>F7>F1.
D. Bioadhesive properties
Ex vivo mucoadhesive time:
The prepared  mucoadhesive  buccal  tablets  were evaluated for  ex vivo  residence  time
using porcine buccal mucosa and the results are tabulated in Table 15. Ex vivo residence
time is the time necessary for complete detachment or erosion of tablet from mucosal
surface without losing integrity. This test reflects the adhesive capacity of polymer used
in formulation. All the tablet formulations showed a residence time of 7.2 h to more than
10 h. As all the polymers used were hydrogel forming hydrophilic matrix and get swelled
to adhere to the mucus surface. The ex vivo residence time relates directly to the swelling
index. The polymer locust bean gum showed maximum of >10 h residence time with
prolonged drug release indicates best formulation as controlled release system.  As the
concentration of locust bean gum increased there was significant increase in residence
time.
Effect of variables on bioadhesive strength:
The mucoadhesive strength of prepared mucoadhesive buccal tablet was studied using
porcine buccal  mucosa  and  the mucoadhesive parameters  are  represented  in  Table15.
Bioadhesion is  generally understood to  define  the ability of  a  biological  or  synthetic
material to “stick” to a mucous membrane, resulting in adhesion of the material to the
tissue for a protracted period of time. In general, bioadhesion is considered to occur in
three  major  stages:  wetting,  interpenetration,  and  mechanical  interlocking  between
biological tissue and polymer. The  mucoadhesive  strength  is  affected by  molecular
weight  of  polymer, contact  time  with  membrane  and degree  of swelling of  the
polymer. Water  uptake  process  produces  polymer  swelling  and  improves  the
consolidation  step  that  increases  the  mobility  of  molecules  and  facilitates  that
interpenetration with the biological tissue layer. So, the polymer swelling is a property
related  to  the  bioadhesion  of  the  system the  constant  and  regression  coefficient  for
bioadhesive strength are as follow:
muco-strnth R4 = +25.33 + 4.55*A + 0.30* B
The Linear model is selected for this response with F - value 75.36 and P- value less than
0.0001  implies  the  model  is  significant.  Figure  32  represent  the  observed  responcse
values compared to that of prdicted values for optimised formula. The effect of A and B
can be further elucidated with the help of response surface plot (Fig 33). Both the factor
A and B  have an synergestic effect on the bioadhesive strengh. At high level of factor A
gave higher value of bioadhesive strength(29) than that of  factor B. If A kept high level
and at all levels of B bioadhesive strength was observed higher values. As increase the
concentration of factor A and B increases the bioadhesive strength.  Locust  bean gum
shows  higher  bioadhesive  strength,  when  compare  to  the  HPMC  K4M  due  to  high
molecular weight, polymer chain flexibility for chain interpenetration and diffusion with
mucin.
Surface pH:
The surface  pH for  all  the  buccal  tablets was from 5.6 to  7.0  which were  nearer  to
salivary pH 6.5-7.5 suggesting that the prepared buccal tablets can be used without the
risk of mucosal irritation and discomfort.
E.  In vitro drug release study after 8 hour:
The  in vitro release of  losartan potassium was performed in phosphate pH 6.8. Total
amount  of  losartan  potassium released  from all  formulations  ranges  from 68.33% to
96.47% in 8 hours  Table 16, 17, 18. Decreased rate of drug release was observed with
increased concentration of polymers. Figure 17, 18, 19 illustrates the release profile of all
formulations. When the tablets contact with water the gel formation of polymers occurs
which acts as rate controlling matrix for the release of drug molecules In this case, effect
of both polymers can be explained by mathematical equation in terms of actual factors:
%DRUG RELEASE AT 8 h R2 = +82.00 -7.64 *A - 6.92 * B
The Linear model is selected for this response with Model F-value 12.73 and p value is
0.0069 indicate the model  is significant. Both the factors A, locust bean gum and B,
HPMC K4M decreases   drug release  from the  tablet.  The  factor  A has  shown more
nagetive effect which indicates that drug release
 
decrease as factor increases. The locust
bean gum is a natural gum it will swellin an aqueous medium to form a gel like matrix
that controls release by acting as a barrier to drug dissolution and diffusion. Locust bean
gum shows the higher controlling effect on the release of drug than the HPMC K4M due
to formation of higher viscous solution. The effect of A and B can be further elucidated
with help of response surface plot figure 31.  At high level of  factor A  lower value of
drug release and at all levels of factor B the release was decreased which indicates factor
A has more significant negative effect.
In vitro drug release study after 1 hour:
Total amount of losartan potassium released from all formulations ranges from 23.06% to
35.26 % in 1 hour table 16, 17, 18. Decreased rate of drug release was observed with
increased concentration of polymers.  Fig 17, 18, 19 illustrates the release profile of all
formulations. Effect  of  both polymers  can  be  explained by mathematical  equation  in
terms of actual factors:
DRUG RELEASE AT 1h R1 = +27.53 - 3.48 *A - 2.38 *B
The  Linear model is selected for this response with Model F-value 4.86 and p value is
0.0557 indicate the model  is significant. Both the factors A, locust bean gum and B,
HPMC K4M decreases   drug release  from the  tablet.  The  factor  A has  shown more
nagetive effect which indicates that drug release
 
decrease as factor increases. factor A
Locust  bean gum shows the higher  controlling effect  on the release of drug than the
HPMC K4M due to formation of higher viscous solution. The effect of A and B factors
can be explained by using of response surface plot ( Figure 29). At high level of  factor A
gave lower value of drug release at all level of factor B which indicates factor A has
significant nagetive effect.
F. Kinetics of drug release:
The drug release data was fitted into the different models like Korsmeyer Peppas, zero
order and Higuchi eqation shown very close and above 0.9 r2 values (table 19). It suggests
that the release of drug from the formulations may follow any one of these models. The r2
values of zero order of all the formulations have shown higher value which indicate the
drug release is directly propertional to the time. But n values range  from 0.458 to 0.562
which  indicate Fickian  diffusion mechanism.  According  to  Higuchi  model,  the  drug
release from matrix is dirctly propertional to square root of time and explains the Fickian
diffusion.  However,  n  values  of  Korsmeyer-Peppas  strongly  indicates  that  diffusion
mechanism is Fickian.
G.  Effect of formulation variable on release exponent:
The 2FI Model was found to be not significant for drug release kinetics with the model F-
valu 1.68 and p value 0.2848 In  this response,  factor  A and B was found to  be  not
significant. So, the model equation is as follows:
n value R3 = +0.51+7.925E-003* A + 3.021E-003* B + 0.028 * A * B
In this response, both the factors  have positive effect. The effect of factor A and B can be
explained with help of the response surface plot (Fig 33).  As the concentration of the
polymer A and B increase the n value increases. The n value of optimized formula found
to be 0.521 which indicates the mechanism of release is Fickian. The factor A with higher
concentration shows the higher effect on value of the release exponent(n) than the factor
B. At high level of factor A gave high value of n at all level of factor B which indicates
that factor A has significant effect.
ANOVA, pure error, lack of fit
The  result  of  ANOVA demostrate  that  the  model  was  singnificant  for  all dependent
variables  (Table 20).  Regression analysis was carried out  to  determine the regression
coefficients. All the independent variables ( Factors) were found to be significant for all
R1,  R2,  R4,  R5,  response  variables.  The  linear  model  were  found  significant  for
R2,R4,R5. So, above result indicate that both the factors play an important role in the
formulation of buccal tablet containing losartan potassium.
6.3. Optimization:
In the numerical optimization techniques, the desirability approch was used to generate
the optimum settings for the formulation. For the optimized formulation, the drug release
at  1st hour  was kept  at  maximize,  the  drug  release at  8  hour  was kept  at  minimize,
bioadhesive strength, hardness were kept at maximize,  release exponent (n) was kept in
the range. The composition of optimized formula is losartan potassium (100 mg), locust
bean  gum (46.59  mg)  and  HPMC K4M (55.45  mg).  The optimized formulation was
prepared according to predicted model and evaluted for responses. A good releationship
between  the  experimental  and  predicted  values  (table  32),  which  confirms  the
precticability and validity of the model.
6.4. Stability Study:
The stability studies were carried out for the optimized formula at 40 ± 2oC/75 ± 5% RH
for  three  months.  Table  35  shows  the  values  of  post-compressional  parameters  after
stability studies at different temperature and humidity conditions. The results indicated
that the tablets did not show any physical changes (hardness, colour and friability) during
the study period and the drug content was found above 98.92% at the end of 3rd month.
This indicates that tablets are fairly stable at storage condition.
CONCLUSION:
The study performed on “formulation and evaluation of mucoadhesive buccal tablets of
losartan potassium” reveals following conclusion:
The  mucoadhesive  buccal  tablets  of  losartan  potassium  could  be  prepared  using
locustbean gum and HPMC K4M by direct compression method.
The IR spectra revealed that, there was no interaction between polymers and drug. All
polymers used were compatible with drug.
All the prepared tablets were in acceptable range of weight variation, hardness, thickness,
friability and drug content as per pharmacopoeial specification.
The surface pH of prepared buccal tablets was in the range of salivary pH, suggested that
prepared tablets could be used without risk of mucosal irritation.
All the buccal tablets showed good residence time of 7.2 H to >10 h, indicated good
adhesive capacity of polymers used.
The CCD was used to find out  the effect  of independent  varibles  on the dependable
variables. The result of  CCD revealed that the locustbean gum and HPMC K4M have
significant effect on the mucoadhesion strenth, swelling index, the drug release at 1 h and
the drug release at 8 h. The observed independent variables were found to be very close
to predicted values of optimized formulation which demonstrates the feasibility of the
optimization procedure in successful development of buccal  tablet  containing losartan
potassium  by  using  locustbean  gum   and  HPMC  K4M.  The  drug  release  form  the
optimized formula was found to be following the zero order kinetics and n value range of
the  Peppas  equation is  0.521,  which indicates  fickian  diffusion  mechanism.  Thus the
release of drug from the dosage form was found to be time dependent.
The  stability  studies  revealed  that  there  was  no  significant  change  in  buccal  tablet
properties with aging at different storage conditions.
Hence,  the  mucoadhesive  buccal  tablets  of  losartan  potassium can  be  prepared  with
enhanced bioavailability and prolonged therapeutic effect for the better management of
hyper tension.
SUMMARY
 The losartan  potassium is  an  angeotensin  II  receptor  antagonist  which is  used  in
treatment  of  hypertension  disorder. The  aim  of  this  work  was  to  develop  a
mucoadhesive  buccal  tablet  for  the  buccal  delivery of  the  losartan  potassium via
buccal mucosa.
 Total 9 formulations of losartan potassium mucoadhesive buccal tablets are designed
to release drug at mucosal site in unidirectional pattern for extended period of time
without wash out of drug by saliva. Locustbean gum and HPMC K4M were selected
as mucoadhesive polymer.
 UV Spectroscopic method was used for the determination of losartan potassium in
methonol at 234 nm.
 The  results  of  the  drug–excipient  compatibility  FT-IR,  DSC studies  revealed  that
there was no chemical interaction between the pure drug and excipients.
 The  tablets  were  prepared  by  direct  compressiom  method.  9  formulations  were
designed  by  using  central  composite  design  using  different  concentrations  of
locustbean gum and HPMC K4M.
 The prepared formulations were evaluated for the precompression parameters such as
angle of repose, bulk density, and % compressibility. All the parameters were found to
be within the limits.
 The  post  compression  parameters  such  as  weight  variation,  thickness,  hardness,
friability,  drug content, swelling index, surface pH, bioadhesive properties such as
bioadhesive time, bioadhesive strength, and  In-vitro dissolution.
 From the data obtained, it is observed that Amongst the various combinations of the
polymers used in the study, the buccal tablets were formulated by direct compression
method using locustbean gum (39 mg) and HPMC K4M (45 mg) exhibited better
results  than  compared  to  those  other  combination  of  polymers  in  different
concentration. The effectiveness of polymers (locustbean gum and HPMC K4M) on
the drug release was explained.
 The Central composite design was utilized using different concentrations of polymers,
locustbean gum (A), HPMC K 4M (B) were selected as independent variables. The
drug release at 1st h (R1), drug release at 8 h (R2), release exponent n value (R3),
mucoadhesive strength (R4) and hardness (R5) were select as dependent variables. A
total  of  9  formulations  was  obtained  and  optimized.  The  developed  optimized
formulation was further  challenged  with  experimentation and was found that,  the
predicted  values  were  in  close  agreement  with  the  actual  values,  indicating  the
validation of the model.
 The  stability  studies  were  carried  out  for  the  optimisation  formulation  and  that
showed no major change in physicho chemical parameters, mucoadhesive strength,
swelling index, drug content, and In-vitro dissolution profile.
 Hence,  based  on  the  above study it  was  concluded  that  in-situ  gel  of  controlled
release Metformin Hydrochloride can be successfully developed on a lab scale.
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